Shots:
- The discontinuation is based on Janssen’s review of all available cusatuzumab data and in consideration of the evolving SOC for AML. Argenx regain its WW rights to cusatuzumab from Cilag
- The P-Ib ELEVATE interim data will support the development of the anti-CD70 Ab in AML, whereas argenx plans to evaluate options to enable a path forward
- Janssen will work with argenx to transition the cusatuzumab program back to argenx. Following the termination, argenx can elect that Janssen operationally support the treatment and follow-up of patients enrolled in ongoing cusatuzumab clinical studies
Click here to read full press release/ article | Ref: Janssen | Image: Janssen
The post Janssen Discontinue its 2018 License Agreement with Argenx for Cusatuzumab first appeared on PharmaShots.
